Kenan ÖZGEN, Erkan Melih ŞAHİN, Aysegül ULUDAĞ, Emel PEKER, Zeynep GÜNAYİ, Yusuf Haydar ERTEKİN

Birinci basamakta irritable barsak sendromu prevalansı

Amaç: İrritabl Barsak Sendromu, organik bozukluğu olmayan bir grup fonksiyonel bağırsak hastalıklarını içerir. Prevalansı tanı kriterleriyle ilişkili olarak %0,5 ile %39 arasında değişmektedir. Bu çalışmada, Roma III kriterlerini kullanarak birinci basamakta İrritabl Barsak Sendromu prevalansını ve özelliklerini araştırmayı amaçladık.Gereç ve Yöntem: Bu toplum tabanlı kesitsel çalışma, aile sağlığı merkezlerine başvuran 500 erişkin ile yapılmıştır. Veriler araştırmacılar tarafından tasarlanan bir anketle alınmış; dışkılama özelliklerini değerlendirmek için Bristol Dışkı Ölçeği ve İrritabl Barsak Sendromu tanısı için ROMA III kriterleri yüz-yüze görüşmelerde doldurulmuştur. Bulgular: 500 katılımcıdan 64'ü (%12,8) önceden İrritabl Barsak Sendromu tanılı olmakla beraber, bunlardan 38'i (%59,4) kadın ve 26'sı (%40,6) erkekti. ROMA III tanı kriterlerine göre yeni tanı alan vaka olmadı. İrritabl Barsak Sendromu tanılı hastalarda kadın/erkek oranı 1,46 idi. Hastaların %34,3'üne aile sağlığı merkezlerinde tanı konulmuş, hastaların %62,5'i aile hekimleri tarafından takip edilmişti.Sonuç: İrritabl Barsak Sendromu prevalansı Kuzey Amerika ve Avrupa'nın güneyi ile benzerdir. İrritabl Barsak Sendromu çoğunlukla kadınları etkilemiş, 30-45 yaşlarda başlamış ve kabızlık-baskın alt tipine daha sık rastlanmıştır. ROMA III tanı kriterleri, hafif ve orta şiddet İrritabl Barsak Sendromu olgularının birinci basamakta tanınması için uygun görünmemektedir.

Anahtar Kelimeler:

Aile sağlığı merkezi, huzursuz bağırsak sendromu, prevalans, Türkiye

Prevalence of irritable bowel syndrome in primary health care

Purpose: Irritable Bowel Syndrome includes a group of functional bowel diseases without organic pathology. The prevalence changes between 0.5% to 39% according to diagnostic criteria. In this study, we aimed to investigate the prevalence and characteristics of IBS in primary health care by using Rome III criteria.Material and Methods: This population-based cross-sectional study was carried out among 500 adults applying to primary healthcare facilities in Çanakkale, Turkey. Data were collected with a data form designed by the researchers, including the Bristol Stool Scale to evaluate defecation characteristics and the ROMA III criteria for the diagnosis of IBS during face-to-face interviews. Results: Of 500 participants, 64 (12.8%) had a previous diagnosis of Irritable Bowel Syndrome who among these were 38 women (59.4%) and 26 men (40.6%). According to the ROMA III criteria no new case was identified. The male: female ratio in Irritable Bowel Syndrome diagnosed patients was 1.46. 34.3% of the patients were diagnosed at a primary healthcare facility, and 62.5% of the patients with Irritable Bowel Syndrome were followed by family practitioners. Conclusion: The prevalence of Irritable Bowel Syndrome found similar with North America and the southern of Europe. Irritable Bowel Syndrome affects mostly females, begins 30 - 45 age, and constipation-predominant subtype was the most frequent. ROMA III diagnostic criteria is not seem to be appropriate to recognize Irritable Bowel Syndrome cases with mild and moderate severity in primary healthcare.

Keywords:

Primary health care, irritable bowel syndrome, prevalence, Turkey,

PDF

___

1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner S. Functional bowel disorders and functional abdominal pain. In Rome II The Functional Gastrointestinal Disorders, 2nd ed (Eds DA Drossman, E Corazziari, NJ Talley, WG Thomson, WE Whitehead):351-432. Philadelphia, Allen Press, 2001.
2. Rome Foundation. Appendix B. Comparison table of Rome II & Rome III adult diagnostic criteria. http://www.romecriteria.org/assets/pdf/20_RomeIII_apB_899-916.pdf (accessed June 2016).
3. Gwee KA, Wee S, Wong ML, Png JCD. The prevalence, symptom characteristics and impact of irritable bowel syndrome in an Asian urban community. Am. J. Gastroenterol. 2004;99:924-31.
4. Lu CL, Chen CY, Lang HC, Luo JC, Wang SS, Chang FY et al.. Current patterns of irritable bowel syndrome in Taiwan: The Rome II questionnaire on a Chinese population. Aliment Pharmacol Ther. 2003;18:1159-69.
5. Ladep NG, Okeke EN, Samaila AA, Agaba EI, Ugoya SO, Puepet FH et al. Irritable bowel syndrome among patients attending general outpatients' clinics in Jos, Nigeria. Eur J Gastroenterol Hepatol. 2007;19:795-9.
6. Okeke EN, Ladep NG, Adah S, Bupwatda PW, Agaba EI, Malu AO. Prevalence of irritable bowel syndrome: a community survey in an African population. Ann Afr Med. 2009;8:177-80.
7. Waehrens R, Ohlsson H, Sundquist J, Sundquist K, Zöller B. Low prevalence of irritable bowel syndrome in primary health care in four Swedish counties. Scand J Prim Health Care. 2013;31:132-7.
8. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS,et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104:1-35.
9. Karaman N, Kürkay C, Yönem Ö. Irritable bowel syndrome prevalence in city centre of Sivas. Turk J Gastroenterol. 2003;14:128-31.
10. Yılmaz S, Dursun M, Ertem M, Canoruc F, Turhanoglu A. The epidemiological aspects of irritable bowel syndrome in Southeastern Anatolia: a stratified randomised community-based study. Int J Clin Pract. 2005;59:361-9.
11. Bommmelar G, Poynard T, Le Pen C, Gaudin AF, Maurel F, Priol G et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol Clin Biol. 2004;28:554-61.
12. Kewin WO, Marvin MS. Irritable bowel syndrome. In Gastrointestinal and liver disease pathophysiology /diagnosis/management, 6th ed. (Eds M Feldman, BF Scharschmidt, MH Sleisenger):1536-48. Philadelphia, Saunders, 1998. 13. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology. 1991;100:998-1005.
14. Heaton KW, Lewis SJ. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920-4.
15. Chang FY, Chen PH, Wu TC, Pan WH, Chang HY, Wu SJ et al. Prevalence of functional gastrointestinal disorders in Taiwan: questionnaire-based survey for adults based on the Rome III criteria. Asia Pac J Clin Nutr. 2012;21:594-600.
16. Dang J, Ardila-Hani A, Amichai MM, Chua K, Pimentel M. Systematic review of diagnostic criteria for IBS demonstrates poor validity and utilization of Rome III. Neurogastroenterol Motil. 2012;24:853-60.
17. Mearin F, Lacy BE. Diagnostic criteria in IBS: useful or not? Neurogastroenterol Motil. 2012;24:791-801.
18. Dorn SD, Morris CB, Hu Y, Toner BB, Diamant N, Whitehead WE et al. Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar. J Clin Gastroenterol. 2009; 43:214-20.
19. Wang AJ, Liao XH, Hu PJ, Liu SC, Xiong LS, Chen MH. A comparison between Rome III and Rome II criteria in diagnosing irritable bowel syndrome. Zhonghua Nei Ke Za Zhi. 2007;46:644-7.
20. Kok L, Elias SG, Witteman BJ, Goedhard JG, Romberg-Camps MJ, Muris JW et al. Application of the Rome III criteria is not likely to reduce the number of unnecessary referrals for colonoscopy in primary care. Eur J Gastroenterol Hepatol. 2013;25:568-74.
21. Shah SS, Bhatia SJ, Mistry FP. Epidemiology of dyspepsia in Mumbai. Indian J Gastroenterol. 2001;20:103–6.
22. Husain N, Chaudhry IB, Jafri F, Niaz SK, Creed F. A population-based study of irritable bowel syndrome in a non-western population. Neurogastroenterol Motil. 2008;20:1022–9.
23. Park DW, Lee OY, Shim SG, Jun DW, Lee KN, Kim HY et al. The differences in prevalence and sociodemographic characteristics of irritable bowel syndrome according to Rome II and Rome III. J Neurogastroenterol Motil. 2010;16:186-93.
24. Boyce PM, Koloski NA, Talley NJ. irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice. Am J Gastroenterology. 2001;95:3176-83.
25. Mearin F, Badia X, Balboa A, Baró E, Caldwell E, Cucala M, et al. Irritable bowel syndrome prevalence varıes enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol. 2000;36:1155-61.
26. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci. 2002;47:225–35.
27. Xiong LS, Chen MH, Chen HX, Xu AG, Wang WA, Hu PJ. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Aliment Pharmacol Ther. 2004;19:1217–24.
28. Wilkins T, Pepitone C, Alex B, Schade RR. Diagnosis and management of IBS in adults. Am Fam Physician. 2012;1:419-26.
29. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17:643-50.
30. NICE: Irritable bowel syndrome in adults. NICE; 2008. http://guidance.nice.org.uk/CG61 (accessed June 2013). 31. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P et al. Guidelines for the management of irritable bowel syndrome. Gut. 2007;56:1770-98.
32. Harkness EF, Grant L, O'Brien SJ, Chew-Graham CA, Thompson DG. Using read codes to identify patients with irritable bowel syndrome in general practice: a database study. BMC Fam Pract. 2013;14:183-9.